A5010544048- Schizophrenia research and treatment
- COVID-19 and Mental Health
- Bipolar Disorder and Treatment
- Long-Term Effects of COVID-19
- Mental Health and Psychiatry
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare professionals’ stress and burnout
- Treatment of Major Depression
- Mental Health Treatment and Access
- Pharmaceutical studies and practices
- Pharmaceutical Practices and Patient Outcomes
- COVID-19 Pandemic Impacts
- Electroconvulsive Therapy Studies
- Mental Health Research Topics
- Cardiovascular Syncope and Autonomic Disorders
- Digital Mental Health Interventions
- Intensive Care Unit Cognitive Disorders
- Urinary and Genital Oncology Studies
- Sexual function and dysfunction studies
- Neurological disorders and treatments
- Psychiatric care and mental health services
- Renal cell carcinoma treatment
- Sleep and related disorders
- Tryptophan and brain disorders
- Adrenal and Paraganglionic Tumors
Imperial College London
2018-2025
West London Mental Health NHS Trust
2016-2025
Hammersmith Hospital
2025
National Health Service
2022-2024
University Children's Hospital Tübingen
2023
University College London
2023
North West London Pathology
2023
University of Milano-Bicocca
2023
Universitätsklinikum Tübingen
2023
The London College
2022
The COVID-19 pandemic has the potential to adversely affect mental health of healthcare workers (HCWs). public system in Greece was already facing serious challenges at outset outbreak following years austerity and an escalating refugee crisis. This multi-center, cross-sectional study aims assess levels associated risk factors anxiety, depression, traumatic stress burnout frontline staff Greece. A total 464 self-selected HCWs six reference hospitals completed a questionnaire comprising...
The burden of the COVID-19 pandemic on health systems and physical mental healthcare workers (HCWs) has been substantial. This cross-sectional study aims to assess effects psychological wellbeing who provide care a vulnerable patient population that have particularly affected during this crisis. A total 387 HCWs from across large urban service completed self-administered questionnaire consisting socio-demographic, lifestyle work-based information validated psychometric scales. Depression...
Most people with bipolar disorder spend a significant percentage of their lifetime experiencing either subsyndromal depressive symptoms or major episodes, which contribute greatly to the high levels disability and mortality associated disorder. Despite importance depression, there are only small number recognised treatment options available. Consecutive failures can quickly exhaust these leading treatment-resistant depression (TRBD). Remarkably few studies have evaluated TRBD those available...
Abstract Background There is limited evidence of genuine equal partnership where power shared with young people mental health difficulties throughout all research stages, particularly in data collection and analysis. Objective To describe how our qualitative study, exploring peoples’ perceptions on the feasibility using technology to detect deterioration, was co‐produced principles co‐production, whilst reflecting impact, challenges recommendations. Methods Young experience were appointed...
Evidence to date suggests that a significant proportion of COVID-19 patients experience adverse psychological outcomes and neuropsychiatric complications. The aim this study was evaluate the effect SARS-CoV-2 infection subsequent hospitalization on mental health, sleep, quality life survivors. Patients were assessed 1−2 months after hospital discharge using standardized screening tools for depression anxiety (HADS), post-traumatic stress disorder (IES-R), insomnia (AIS), (EQ-5D-5L)....
Objective: The objective of the study was to demonstrate whether N-methylo-d-aspartate antagonist, amantadine, can safely ameliorate tardive dyskinesia (TD) without deteriorating mental state patients. Methods: Twenty-two TD patients, with a mean age 52 years, participated in study. A double-blind, placebo-controlled, crossover design used. Patients were randomly assigned receive either amantadine or placebo for 2 weeks followed by washout period 4 days. Subsequently, groups crossed over,...
Background Technological interventions may help support and improve mental health. However young peoples' perspectives on using different technologies to detect deteriorating health in those already diagnosed with a condition is lacking. The study aim was explore the of patients feasibility acceptability wearables, social media deterioration. Methods co-produced adults past difficulties. Semi-structured interviews were conducted severe private room at community site. Data triangulated by...
Background Despite the availability of effective therapies, many patients with major depressive disorder (MDD) develop treatment-resistant depression (TRD). Aims To evaluate and compare prescribing patterns, contact specialist services treatment outcomes in MDD TRD. Method This was a retrospective analysis linked primary secondary care National Health Service data north-west London Discover-NOW data-set. Eligible were adults who had diagnostic codes for been prescribed at least one...
Abstract Background Major depressive disorder (MDD) is a leading cause of global disability. Despite availability effective therapies, many patients with MDD develop treatment-resistant depression (TRD). Aims To evaluate and compare treatment outcomes, comorbidities healthcare resource usage costs in major Methods This was population-based, retrospective analysis linked primary secondary care NHS data the northwest London Discover-NOW dataset. access platform for longitudinal Whole Systems...
Abstract Loss of glutamatergic terminals is hypothesised to contribute excitation-inhibition imbalance in schizophrenia, supported by evidence that the normal positive association between glutamate concentrations and synaptic terminal density not found patients with chronic schizophrenia. However, it unknown whether relationship levels altered early course illness. To address this, we investigated [ 11 C]UCB-J distribution volume ratio (DVR) markers healthy volunteers (HV)...
Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM two-injection start initiation regimen 400-TIS) an alternative to one injection plus 14 days oral aripiprazole supplementation. This survey investigated real-world experiences European healthcare professionals (HCPs) 400-TIS. Physicians and nurses in Germany, Italy, United Kingdom who had prescribed and/or administered 400-TIS ≥ 3 times patients...
Background LAIs with longer dosing intervals appear to be associated improved clinical outcomes and added real-world benefits in the management of schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides longest interval, twice-yearly dosing, among all currently available LAIs. In trials PP6M was found non-inferior preventing relapses patients schizophrenia compared three monthly formulation (PP3M) though real world data remain limited. Therefore, aim this study evaluate...
Background: Previous studies showed a linear correlation between partial compliance with an oral antipsychotic medication and hospitalisation risk among patients schizophrenia. Long-acting injections (LAIs) may significantly improve adherence reduce relapse in psychosis. The aim of this study was to evaluate the relationship level 1-monthly paliperidone palmitate (PP1M) rates. Methods: This naturalistic, mirror-image examining retention, rates 3 years pre- post-PP1M initiation. Compliance...